Mary M. Rozenman, See Remarks at Aimmune Therapeutics, Inc. (AIMT), sold 75,010 shares at $38.83 ($2.9M) on 2017-12-26, disclosed to the SEC on 2017-12-28.
Open-market sale of $2.9M AIMT by See Remarks. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $38.73 | 6,400 | $248K | 8.5% |
| 2 | $38.80 | 4,310 | $167K | 5.7% |
| 3 | $38.82 | 10,700 | $415K | 14.2% |
| 4 | $38.82 | 11,000 | $427K | 14.6% |
| 5 | $38.83 | 8,800 | $342K | 11.7% |
| 6 | $38.83 | 11,000 |
| $427K |
| 14.6% |
| 7 | $38.83 | 11,000 | $427K | 14.6% |
| 8 | $39.15 | 3,600 | $141K | 4.8% |
| 9 | $39.23 | 1,800 | $71K | 2.4% |
| 10 | $39.23 | 1,500 | $59K | 2.0% |
| 11 | $39.25 | 1,500 | $59K | 2.0% |
| 12 | $39.25 | 1,500 | $59K | 2.0% |
| 13 | $39.26 | 700 | $27K | 0.9% |
| 14 | $39.28 | 1,200 | $47K | 1.6% |
| Total | $38.88 avg | 75,010 | $2.9M | 100% |